About PRA Health Sciences
PRA Health Sciences, Inc. is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. The Company's integrated services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. The Company's service offerings include Product Registration Services, which includes Phase IIb through III product registration trials and Phase IV trials, inclusive of post-marketing commitments and registries; Strategic Solutions, which provides Embedded Solutions and functional outsourcing services, and Early Development Services, which includes Phase I through Phase IIa clinical trials and bioanalytical laboratory services.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Laboratories & Research
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: PRAH
- Previous Close: $61.02
- 50 Day Moving Average: $58.00
- 200 Day Moving Average: $54.92
- 52-Week Range: $39.25 - $61.92
- Trailing P/E Ratio: 57.57
- Foreward P/E Ratio: 16.90
- P/E Growth: 1.04
- Market Cap: $3.76B
- Outstanding Shares: 61,597,000
- Beta: 0.54
- Net Margins: 4.86%
- Return on Equity: 21.25%
- Return on Assets: 6.86%
Companies Related to PRA Health Sciences:
- Debt-to-Equity Ratio: 1.20%
- Current Ratio: 1.25%
- Quick Ratio: 1.25%
What is PRA Health Sciences' stock symbol?
PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."
Where is PRA Health Sciences' stock going? Where will PRA Health Sciences' stock price be in 2017?
7 brokerages have issued twelve-month price targets for PRA Health Sciences' shares. Their predictions range from $47.00 to $67.00. On average, they expect PRA Health Sciences' stock price to reach $59.29 in the next twelve months.
When will PRA Health Sciences announce their earnings?
PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.
What are analysts saying about PRA Health Sciences stock?
Here are some recent quotes from research analysts about PRA Health Sciences stock:
According to Zacks Investment Research, "PRA Health Sciences, Inc. operates as a global contract research organizations providing outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in the areas of cardio-metabolic, biosimilars, infectious diseases, immunology, neurology and psychiatry, oncology and hematology, rare diseases, and respiratory needs. The Company engages in bioanalytical laboratory, clinical pharmacology, clinical development, strategic solutions, post marketing research, clinical informatics, clinical diagnostics, and safety and risk management activities. PRA Health Sciences, Inc. is based in Raleigh, North Carolina. " (11/9/2016)
KeyCorp analysts commented, "By our models, the strength of PRAH's backlog (up 16 percent YOY) and bookings (1.25xR4Q) sets up for above-consensus performance," analyst Donald Hooker wrote in a note.Hooker expects constant currency revenue growth of 13.8 percent in 2016 (consensus: 12.7 percent) and 10.9 percent in 2017 (consensus: 9.5 percent), which should boost profit margins. The analyst forecast 2016 EPS of $2.46 (consensus: $2.43), and 2017 EPS of $2.96 (consensus: $2.82).Related Link: Raymond James Sees Lingering Risks At OraSure, DowngradesEven assuming a modest slowdown in backlog conversion, we think revenues should come in toward the high end of management's 2016 guidance with significant backlog left over for a strong 2017 and 2018," Hooker highlighted.Other Expectations For PRA HealthThe analyst also models EBITDA growth of almost 13 percent in 2017, which is well above the peer group average about 10 percent.In addition, the analyst noted that investors under appreciate the bookings strength from PRA Health's investments in analytics that include Predictivv cloud-based technology platform and its recent acquisition of Nextrials, an electric data capture (EDC) vendor. Hooker said, "Management has been developing retroactive and predictive algorithms over the past eight years, and we believe this work may now be starting to show up in bookings."[M]anagement has recently addressed PRAH's indebtedness and ownership concentration, which reduces two of the largest overhangs on the shares, in our view," (6/13/2016)
Who owns PRA Health Sciences stock?
PRA Health Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Marshall Wace LLP (2.05%), Columbia Wanger Asset Management LLC (1.91%), FMR LLC (1.63%), Ranger Investment Management L.P. (1.21%), Alyeska Investment Group L.P. (1.11%) and Russell Investments Group Ltd. (1.02%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour and Pra Investors LP Kkr.
Who sold PRA Health Sciences stock? Who is selling PRA Health Sciences stock?
PRA Health Sciences' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Two Sigma Investments LP, Loomis Sayles & Co. L P, Turner Investments LLC, Guggenheim Capital LLC, GSA Capital Partners LLP, Cipher Capital LP and Tudor Investment Corp Et Al. Company insiders that have sold PRA Health Sciences stock in the last year include Colin Shannon, David W Dockhorn, Linda Baddour and Pra Investors LP Kkr.
Who bought PRA Health Sciences stock? Who is buying PRA Health Sciences stock?
PRA Health Sciences' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Marshall Wace LLP, Alyeska Investment Group L.P., Columbia Wanger Asset Management LLC, Allianz Asset Management AG, Dimensional Fund Advisors LP, Ranger Investment Management L.P. and Axiom International Investors LLC DE.
How do I buy PRA Health Sciences stock?
Shares of PRA Health Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of PRA Health Sciences stock cost?
One share of PRA Health Sciences stock can currently be purchased for approximately $61.02.